Veldurthy et al. suggest that this effect is associated with dasatinib's inhibitory activity not only against BCR-ABL but also against SFK (Src Family Kinases) which may imply that this TKI should be considered in the situation of CML and B-CLL coexistence. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.